Form D · Pharmaceuticals

Acerus Pharmaceuticals Corp

Mississauga, A6 · CIK 0001527246

Offering snapshot reported May 5, 2016 · SEC filing

Reported sold
$2M
Offering amount: $2M
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Apr 27, 2016
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
May 5, 2016Initial$2,000,000No comparison1SEC filing
Aug 13, 2014Initial$2,131,268No comparison2SEC filing
Aug 3, 2011Initial$6,847,846No comparison16SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-262614

Source: Form D, filed May 5, 2016. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Norma Beauchamp Director
Bruce D. Brydon Director, Executive
Dr. Nathan Bryson Executive
Nathan Bryson Executive
Dr. Michael Bumby Executive
James Butler Director
Borys Chabursky Director
Larry Davis Director
Douglas Deeth Director
John Friedrichsen Director
Stephen Gregory Director
Matthew Hawkins Executive
Kenneth Howling Executive
Ian Ihnatowycz Director
Eugene Melnyk Promoter
Matthew Pfeffer Executive
Robert Podruzny Director
Rolf K. Reininghaus Director
Tom Rossi Director, Executive
Jeffrey Sherman Director
Mark L. Thompson Executive
D. Lorne Tyrell Director
Josef Vejvoda Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
2486 Dunwin Drive
Mississauga, A6, L5L 1J9